Patients with multiple myeloma who receive IVIG prophylaxis during treatment with teclistamab have fewer infections and better overall survival compared to those who do not receive IVIG. The study included 225 patients with relapsed and/or refractory multiple myeloma, showing that IVIG prophylaxis led to a longer duration of infection-free survival and almost threefold longer median overall survival. Starting IVIG within 30 days of therapy initiation is recommended. Results were consistent regardless of whether patients received standard-of-care teclistamab or investigational BCMA-directed bsAb. IVIG prophylaxis was associated with better progression-free survival and overall survival, but study limitations included a lack of randomization.
Source link
IVIG Prophylaxis in Myeloma Cuts Infections, Ups Survival
